amphotericin-b and Leukemia--Megakaryoblastic--Acute
amphotericin-b has been researched along with Leukemia--Megakaryoblastic--Acute* in 2 studies
Reviews
1 review(s) available for amphotericin-b and Leukemia--Megakaryoblastic--Acute
Article | Year |
---|---|
Diagnosis and successful treatment of fusariosis in the compromised host.
We present six cases of fusariosis caused by Fusarium solani that were diagnosed over a three-year period in 166 adult patients undergoing chemotherapy for acute leukemia. Necrotic skin lesions were evident in four patients, fungemia in three, and a deep cellulitis around a great toe nail at the time of a febrile illness in two. The mean minimal inhibitory concentration (MIC) of amphotericin B was 3.3 micrograms/mL and of miconazole, 5.3 micrograms/mL; all isolates were resistant to 5-fluorocytosine. All patients received amphotericin B (1.0-1.5 mg/kg per d) plus 5-fluorocytosine. In contrast to results found in the literature, five patients had resolution of their infections, and the one patient who died had necropsy evidence of disseminated fusariosis. Review of our cases and of the literature did not reveal a definitive source for the organism or its portal of entry. Fusarium spp. must be recognized as opportunistic pathogens that cause a potentially fatal infection in compromised patients. Topics: Adult; Amphotericin B; Female; Flucytosine; Fusarium; Humans; Immune Tolerance; Leukemia; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Prolymphocytic; Male; Middle Aged; Mycoses; Opportunistic Infections | 1988 |
Other Studies
1 other study(ies) available for amphotericin-b and Leukemia--Megakaryoblastic--Acute
Article | Year |
---|---|
Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.
The management of invasive aspergillosis in patients with hematological malignancies remains controversial. A major problem is how to manage patients who had invasive aspergillosis during remission induction and consolidation therapy and then undergo SCT. Indeed in these patients the mortality rate related to invasive aspergillosis recurrence remains unacceptably high. We report two cases of patients who underwent remission induction for AML, developed invasive aspergillosis during antifungal prophylaxis with itraconazole, failed amphotericin B deoxycholate and liposomal amphotericin B treatment, were successfully treated with voriconazole and eventually underwent SCT with voriconazole prophylaxis without reactivation of invasive aspergillosis. Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxycholic Acid; Drug Combinations; Drug Resistance, Fungal; Etoposide; Fatal Outcome; Humans; Immunocompromised Host; Itraconazole; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelomonocytic, Acute; Liposomes; Lung Diseases, Fungal; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Triazoles; Voriconazole | 2002 |